Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.
about
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make BiobettersCNS active O-linked glycopeptidesConsequences of periodic α-to-β(3) residue replacement for immunological recognition of peptide epitopes.Library construction, selection and modification strategies to generate therapeutic peptide-based modulators of protein-protein interactions.Prolonged Acetaminophen-Protein Adduct Elimination During Renal Failure, Lack of Adduct Removal by Hemodiafiltration, and Urinary Adduct Concentrations After Acetaminophen Overdose.Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice.Original insights on thrombospondin-1-related antireceptor strategies in cancer.Peptide Backbone Composition and Protease Susceptibility: Impact of Modification Type, Position, and Tandem Substitution.Delivery of ziconotide to cerebrospinal fluid via intranasal pathway for the treatment of chronic pain.Intricacies for posttranslational tumor-targeted cytokine gene therapy.Improved method for quantitative analysis of the cyclotide kalata B1 in plasma and brain homogenateEarly engineering approaches to improve peptide developability and manufacturability.Strategic approaches to optimizing peptide ADME propertiesClinical pharmacology of bispecific antibody constructs.Short peptides interfering with signaling pathways as new therapeutic tools for cancer treatment.A peptide derivative serves as a fibroblast growth factor 2 antagonist in human gastric cancer.Immunogenicity and pharmacokinetics of short, proline-rich antimicrobial peptides.Clinical Pharmacokinetics and Pharmacodynamics of Colistin.α9-containing nicotinic acetylcholine receptors and the modulation of pain.Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake.Degradation Paradigm of the Gut Hormone, Pancreatic Polypeptide, by Hepatic and Renal Peptidases.Peptides as Therapeutic Agents for Dengue Virus.Modeling energy intake and body weight effects of a long-acting amylin analogue.Peptibodies: An elegant solution for a long-standing problem.Development of Potent, Protease-Resistant Agonists of the Parathyroid Hormone Receptor with Broad β Residue Distribution.Population pharmacokinetics of exendin-(9-39) and clinical dose selection in patients with congenital hyperinsulinism.Transferon™, a peptide mixture with immunomodulatory properties is not immunogenic when administered with various adjuvants.Biodistribution of the cyclotide MCoTI-II, a cyclic disulfide-rich peptide drug scaffold.Exploitation of the Ornithine Effect Enhances Characterization of Stapled and Cyclic Peptides.The peptide Phα1β, from spider venom, acts as a TRPA1 channel antagonist with antinociceptive effects in mice.Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers.Strengthening peptide-based drug activity with novel glyconanoparticleModel peptides containing the 3-sulfanyl-norbornene amino acid, a conformationally constrained cysteine analogue effective inducer of 310-helix secondary structuresADME for Therapeutic Biologics: Antibody-Derived Proteins and Proteins with Novel Scaffolds
P2860
Q26801319-D658338A-3773-453E-84D8-0B3DDF7960ECQ27021529-F04025C2-0F82-4A9E-96E4-B2685094948AQ35213100-4192FE94-984A-4BA2-9DD8-F09B9093A735Q35532355-034D493D-D4DD-4ACA-AAFC-C569FC8A40A3Q35749131-1D7905F9-3352-454A-A175-5C33A8B6B42CQ36204764-A92BD3A9-9955-4B32-8059-6B936206A598Q36221374-E61FD2D7-B5CC-4852-8FD9-CF5F48C3CBEDQ36488030-7258F5E4-49D4-4A10-B0CE-BA927264885CQ36563732-E8166156-2E93-4304-808C-0080218321C3Q37392885-973EDA7E-9A49-49C9-B1F9-CA015CE22948Q37462124-161002DA-A50D-42ED-BC52-55028DEFA7B5Q38262021-4E732B5F-8FF8-44A3-B777-E19A2EA87B48Q38264736-5A7A9FEB-0814-43C7-804A-C1BC40CDC7F5Q38364459-BFE151BD-CB4F-47F4-BD75-D62A845C1433Q38767147-FD6A2322-C6DE-4A9F-88A6-1B2911FBA526Q38884499-86D859A3-0108-4AED-ADAC-B706CE884561Q38970681-3C41E6E4-CF4B-4A1F-BA36-30103C94D377Q39333751-69D3F4BE-E4B5-4513-8133-AD2AC035FD75Q39405111-9C505AEF-5D53-49D7-ADEE-DD8961A43F7AQ41674388-A234F3C6-3778-4F8F-9BF6-805AB62518AFQ44945151-D175B8DF-DE8E-4EDC-8231-B26416049124Q45323856-4DC0CC43-14AA-4EF9-B192-9B24DD883C08Q47175680-3EBB446F-704F-42F4-8BF8-4459281A473CQ47229048-167F4137-CFEA-43FE-BC17-44D939DE0BD4Q47416630-0BE50129-9738-450D-AFF2-5CDB1E34ED6EQ47872785-C1772C26-B365-4C34-A3D2-5A4E21C971AFQ48126195-B0D06C44-E657-4419-941A-BCA6109158A7Q48869308-BE3AE1E6-9EEE-40D7-A8FC-6A28AE0EF0EDQ50881656-CABE7322-5B81-4D2F-9BE5-5046BAFC83F6Q51375560-34452E7C-D583-4018-AED2-EF093CD862D0Q53186529-79FFC047-4EC1-4BCE-B06A-AB8FB780E51DQ58691719-0FEC2CCC-F6D0-4349-9380-77CAF5879104Q58857788-483F21F9-EC60-4386-857B-426748E861AAQ58869554-208BC851-0AFB-4404-827F-98A1C26973D8
P2860
Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pharmacokinetics and pharmacok ...... tions of therapeutic peptides.
@en
type
label
Pharmacokinetics and pharmacok ...... tions of therapeutic peptides.
@en
prefLabel
Pharmacokinetics and pharmacok ...... tions of therapeutic peptides.
@en
P2860
P1476
Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides
@en
P2093
P2860
P2888
P304
P356
10.1007/S40262-013-0079-0
P577
2013-10-01T00:00:00Z
P5875
P6179
1026731644